In this episode of the Oncology Brothers podcast, we continue our three-part CME series on small cell lung cancer, focusing specifically on adverse events and management strategies for extensive stage small cell lung cancer. We had the pleasure of welcoming Dr. Misty Shields from Indiana University to discuss the latest treatment options and their associated side effects.
We began by reviewing the exciting new data presented at ASCO 2025, highlighting the overall survival benefits of treatments like lurbinectedin and atezolizumab, and tarlatamab. Dr. Shields confirmed that her treatment algorithm for patients with good performance status would involve starting with chemoimmunotherapy, followed by maintenance therapy with lurbinectedin and immunotherapy, and considering tarlatamab upon disease progression.
Dr. Shields emphasized the importance of managing common side effects associated with these treatments, particularly hematologic toxicities, liver function abnormalities, and the challenges of distinguishing between side effects from immunotherapy and lorbanectin. We discussed the role of growth factors and the use of trilocyclib in managing hematologic toxicities, as well as the importance of supportive care, including palliative care referrals.
As we delved into tarlatamab, Dr. Shields shared insights on managing cytokine release syndrome (CRS) and the logistical considerations for community oncologists when administering this therapy. We also touched on other side effects such as fatigue, taste changes, and myalgias, stressing the need for proactive management and patient education.
In closing, Dr. Shields highlighted the rapidly changing landscape of small cell lung cancer treatment and the importance of close monitoring and supportive care to improve patient outcomes. We reiterated that while the overall survival benefits may not be dramatic, any improvement is significant in the context of this devastating disease.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc